New approaches to pulmonary hypertension: will therapies in mice work in humans?
Nabel
E G
EG
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D015740:Calcitonin Gene-Related Peptide / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000628:therapy*; D000860:Hypoxia / Q000150:complications* / Q000503:physiopathology; D008168:Lung / Q000378:metabolism; D051379:Mice; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D011498:Protein Precursors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000502:physiology; D014661:Vasoconstriction; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D010726:Phosphodiesterase Inhibitors; D015221:Potassium Channels; D011498:Protein Precursors; D011993:Recombinant Fusion Proteins; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; C076404:preprocalcitonin gene-related peptide; D015740:Calcitonin Gene-Related Peptide